ProTgen Information

ProTgen is a biotechnology company developing first-in-class targeted Notch activator biotherapeutics, designed to activate the body's own progenitors to produce new T cells — a single mechanism with potential across acute and chronic settings of immune insufficiency. T-cell diversity and thymic function independently predict survival, immunotherapy response, and age-related disease — and no approved therapy restores them. Published studies link thymic function and T-cell diversity to clinical outcomes, from population-scale cohorts to clinical proof of concept. ProTgen was founded on more than 20 years of research in T-cell development and Notch signaling biology. Program-level detail is shared directly with prospective partners. Learn more at protgen.bio.